News update ProQR agreement with Laboratoires Théa for Sepofarsen and Ultevursen Inherited Retinal Disease Programs

Written by Andrew Bolan

ProQR has announced an agreement with Laboratoires Théa to acquire ProQR’s sepofarsen and ultevursen inherited retinal disease (IRD) programs.

Beatrice, a young girl living with LCA10, playing in the ball pit at ProQR

In August 2022 ProQR decided to focus exclusively on the development of the Axiomer® RNA editing technology platform. At that time, ProQR also announced that it would seek a partner to continue the development of its IRD programs. ProQR is pleased now to announce that Laboratoires Théa (Théa), will continue the development of the sepofarsen and ultevursen IRD programs.

Théa’s proven expertise in (...) eye care products makes them the ideal company to continue the development of sepofarsen and ultevursen.

Daniel A. de Boer, Chief Executive Officer of ProQR Therapeutics

“Théa’s proven expertise in the research, development, and commercialization of eye care products makes them the ideal company to continue the development of sepofarsen and ultevursen for patients with rare genetic eye diseases," says Daniel A. de Boer, founder and CEO of ProQR. "We look forward to continuing to advance our Axiomer RNA editing platform, with an initial focus on targets for cholestatic and cardiovascular diseases, as we seek to develop a new class of therapies for patients with high unmet need."

Within Théa, a fully dedicated team specializing in inherited retinal disorders and a new organization are currently being set up to manage these two projects. More information on the next steps for these programs will be available in the coming weeks from Théa.

We look forward to returning these assets into the clinic.

Jean-Frédéric Chibret, President of the Théa group

“For nearly 30 years, Théa has been committed to bringing the most modern and diverse range of innovative ophthalmic products to the market for the benefits of eye care practitioners and patients. We are very excited to continue the development of sepofarsen and ultevursen for patients," says Jean-Frédéric Chibret, President of the Théa group. "These two programs can deliver hope for patients suffering from retinal diseases that lead to blindness. We look forward to returning these assets into the clinic.”

The divestment of sepofarsen and ultevursen supports ProQR’s strategic focus on the Axiomer® RNA editing technology platform and continued advancement of pipeline programs, AX-0810 and AX-1412, focused on genetic diseases originating in the liver. The transaction is expected to close in the third quarter of 2023.

For further information or enquiries about the announcement today, please email: patientinfo@proqr.com.